Oak Family Advisors LLC Buys Shares of 348,025 Kenvue Inc. $KVUE

Key Points

• Oak Family Advisors LLC bought a new stake of 348,025 shares of Kenvue (NYSE:KVUE) in Q4, valued at about $6.00 million, making KVUE 1.6% of the firm's holdings and its 19th-largest position.
• Kenvue beat estimates for the most recent quarter with $0.32 EPS vs. $0.27 expected and revenue of $3.91 billion, up 4.5% year-over-year.
• The company announced a quarterly dividend of $0.2075 (annualized $0.83) for a yield of 4.7%, but the dividend payout ratio is elevated at about 107.8%.

Oak Family Advisors LLC bought a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 348,025 shares of the company's stock, valued at approximately $6,003,000. Kenvue makes up 1.6% of Oak Family Advisors LLC's holdings, making the stock its 19th biggest position.

Several other large investors also recently added to or reduced their stakes in the stock. Physician Wealth Advisors Inc. grew its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock valued at $26,000 after buying an additional 618 shares in the last quarter. Versor Investments LP grew its holdings in Kenvue by 2.8% in the 3rd quarter. Versor Investments LP now owns 26,016 shares of the company's stock valued at $422,000 after buying an additional 716 shares in the last quarter. Philip James Wealth Mangement LLC grew its holdings in Kenvue by 5.5% in the 4th quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company's stock valued at $240,000 after buying an additional 726 shares in the last quarter. Titleist Asset Management LLC grew its holdings in Kenvue by 1.6% in the 3rd quarter. Titleist Asset Management LLC now owns 50,957 shares of the company's stock valued at $827,000 after buying an additional 796 shares in the last quarter. Finally, Kestra Private Wealth Services LLC grew its holdings in Kenvue by 1.6% in the 4th quarter. Kestra Private Wealth Services LLC now owns 52,517 shares of the company's stock valued at $906,000 after buying an additional 814 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

NYSE KVUE opened at $17.74 on Friday. The stock has a fifty day simple moving average of $17.65 and a 200-day simple moving average of $17.24. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The company has a current ratio of 0.96, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The stock has a market cap of $34.06 billion, a PE ratio of 23.04, a P/E/G ratio of 4.01 and a beta of 0.55.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter in the prior year, the company earned $0.24 EPS. Kenvue's revenue was up 4.5% on a year-over-year basis. Equities analysts anticipate that Kenvue Inc. will post 1.1 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be paid a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue's dividend payout ratio is presently 107.79%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the company a "hold" rating in a report on Wednesday, February 18th. Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Wednesday, April 15th. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an "equal weight" rating for the company in a report on Tuesday, April 14th. Argus upgraded Kenvue to a "hold" rating in a report on Friday, March 6th. Finally, UBS Group lowered their price target on Kenvue from $19.00 to $18.00 and set a "neutral" rating for the company in a report on Tuesday, April 7th. Three analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.